endpts.com·Apr 13, 2026
Click Therapeutics has laid off over 25% of its workforce shortly after securing $50 million in Series D funding from Boehringer Ingelheim.
For someone interested in healthtech and digital therapeutics, the key takeaway is the strategic realignment of Click Therapeutics following their Series D funding from Boehringer Ingelheim. This highlights the importance of balancing financial influx with operational efficiency, suggesting a potential shift in focus towards optimizing resources for scalable growth in the digital therapeutics space.